These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38049114)

  • 41. Four-factor prothrombin complex concentrate use for on-label versus off-label indications: a retrospective cohort study.
    Adkins BD; Shaim H; Abid A; Gonzalez A; DeAnda A; Yates SG
    J Thromb Thrombolysis; 2023 Jan; 55(1):74-82. PubMed ID: 35699871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.
    Zemrak W; Manuel F; Smith KE; Rolfe S; Hayes T; Trowbridge RL; Carlone B; Seder D
    J Thromb Thrombolysis; 2019 Feb; 47(2):263-271. PubMed ID: 30443817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.
    Frontera JA; Bhatt P; Lalchan R; Yaghi S; Ahuja T; Papadopoulos J; Joset D
    J Thromb Thrombolysis; 2020 Jan; 49(1):121-131. PubMed ID: 31664662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials.
    Milling TJ; Refaai MA; Sarode R; Lewis B; Mangione A; Durn BL; Harman A; Lee ML; Goldstein JN
    Acad Emerg Med; 2016 Apr; 23(4):466-75. PubMed ID: 26822172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery.
    Ortmann E; Besser MW; Sharples LD; Gerrard C; Berman M; Jenkins DP; Klein AA
    Anesth Analg; 2015 Jul; 121(1):26-33. PubMed ID: 25822921
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
    Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
    Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial.
    Bartoszko J; Callum J; Karkouti K;
    Can J Anaesth; 2021 Dec; 68(12):1789-1801. PubMed ID: 34523108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals.
    Santibanez M; Lesch CA; Lin L; Berger K
    J Crit Care; 2018 Dec; 48():183-190. PubMed ID: 30218958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes Following Three-Factor Inactive Prothrombin Complex Concentrate Versus Recombinant Activated Factor VII Administration During Cardiac Surgery.
    Harper PC; Smith MM; Brinkman NJ; Passe MA; Schroeder DR; Said SM; Nuttall GA; Oliver WC; Barbara DW
    J Cardiothorac Vasc Anesth; 2018 Feb; 32(1):151-157. PubMed ID: 29217234
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings.
    Hitchcock ZR; Smith SD; Le LT; Lees LR; Brandt MD
    J Pharm Pract; 2023 Apr; 36(2):221-226. PubMed ID: 34231410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. On-label compared to off-label four-factor prothrombin complex concentrate use: a retrospective, observational study.
    Cho BC; Jung YH; DeMario VM; Lau E; Podlasek SJ; Grant MC; Gehrie EA; Frank SM
    Transfusion; 2019 Aug; 59(8):2678-2684. PubMed ID: 31121073
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Institution of prothrombin complex concentrate protocols is associated with a reduction in plasma administration at a Tertiary Care Hospital.
    Carabini LM; Budd AN; Bochey P; Shayan S; Ramsey G; McCarthy RJ
    J Clin Anesth; 2021 Jun; 70():110164. PubMed ID: 33485109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Four-Factor Prothrombin Complex Concentrate for Coagulopathy Reversal in Patients With Liver Disease.
    Huang WT; Cang WC; Derry KL; Lane JR; von Drygalski A
    Clin Appl Thromb Hemost; 2017 Nov; 23(8):1028-1035. PubMed ID: 27628534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices.
    Rimsans J; Levesque A; Lyons E; Sylvester K; Givertz MM; Mehra MR; Stewart GC; Connors JM
    J Thromb Thrombolysis; 2018 Aug; 46(2):180-185. PubMed ID: 29785470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of prothrombin complex concentrate (PCC) versus fresh frozen plasma (FFP) in reducing perioperative blood loss in cardiac surgery: study protocol for a non-inferiority, randomised controlled trial.
    Pei L; Sun C; Lv H; Zhang Y; Shi J
    BMJ Open; 2022 Feb; 12(2):e051072. PubMed ID: 35144945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.
    Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB
    Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal.
    Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K
    J Am Pharm Assoc (2003); 2024; 64(2):395-401. PubMed ID: 37952844
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Off-label use of 4-factor prothrombin complex concentrate is common despite little known benefit: A retrospective study.
    Scharman CD; Shatzel JJ; Kim E; DeLoughery TG
    Eur J Haematol; 2018 Sep; 101(3):349-353. PubMed ID: 29862565
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
    Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
    Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage.
    Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME
    Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.